Immune Globulin Intravenous (Human), 10% Triple Virally Reduced Solution ( DrugBank: - )


1 disease
IDDisease name (Link within this page)Number of trials
63Idiopathic thrombocytopenic purpura1

63. Idiopathic thrombocytopenic purpura


Clinical trials : 363 Drugs : 212 - (DrugBank : 43) / Drug target genes : 47 - Drug target pathways : 138
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00162006
(ClinicalTrials.gov)
January 13, 20038/9/2005Efficacy and Safety Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Adult Subjects With Chronic Idiopathic Thrombocytopenic PurpuraProspective Open-Label Study of the Efficacy and Safety of Immune Globulin Intravenous (Human), 10% TVR Solution in Adult Subjects With Chronic Idiopathic Thrombocytopenic PurpuraImmune Thrombocytopenic Purpura (ITP)Drug: Immune Globulin Intravenous (Human), 10% Triple Virally Reduced SolutionBaxalta now part of ShireNULLCompleted18 Years65 YearsAll28Phase 2Czechia;Germany;Hungary;Poland;Czech Republic